The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
本发明涉及公式I的化合物及其药学上可接受的盐或溶剂化物,以及制备和使用这些化合物的方法。
Pyridopyrimidinone Inhibitors of Pl3Kalpha
申请人:Baik Tae-Gon
公开号:US20090270430A1
公开(公告)日:2009-10-29
The invention is directed to Compounds of Formula I:
and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
本发明涉及化合物I式及其药学上可接受的盐或溶剂化物,以及制备和使用这些化合物的方法。
METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA
申请人:Lamb Peter
公开号:US20100209420A1
公开(公告)日:2010-08-19
The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.
(Formula I)
PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER
申请人:Buhr Chris A.
公开号:US20100150827A1
公开(公告)日:2010-06-17
The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.
Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
申请人:Exelixis, Inc.
公开号:US08044062B2
公开(公告)日:2011-10-25
The invention is directed to Compounds of Formula I:
and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.